How does Fycompa work (per its mechanism of action)?
Fycompa (perampanel) is an anti-seizure medicine that works by changing how brain cells respond to the neurotransmitter glutamate. It blocks AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, which are a major route for fast excitatory signaling in the brain. By inhibiting AMPA receptor activity, perampanel reduces excessive excitatory transmission that can contribute to seizure activity. [1]
Why does blocking AMPA receptors help with seizures?
AMPA receptors mediate rapid excitatory signals in neural circuits. In many seizure disorders, abnormal neuronal firing involves too much excitatory drive. Perampanel’s AMPA receptor antagonism lowers that excitatory signaling, which helps limit the spread and intensity of seizure activity. [1]
What kind of drug is Fycompa compared with others?
Because it directly antagonizes AMPA receptors, Fycompa has a different target than many other antiseizure medications that act on:
- voltage-gated sodium channels,
- GABA (inhibitory signaling),
- calcium channels,
- or other glutamate-related mechanisms.
That AMPA-receptor mechanism is part of why Fycompa is often used when seizures aren’t controlled with other therapies. [1]
Drug safety and interaction angle tied to its mechanism
AMPA receptor blockade affects excitatory neurotransmission broadly in the CNS, which is consistent with central nervous system side effects seen with perampanel and the need to consider interactions that can alter perampanel exposure. (Specific prescribing cautions depend on the product label.) [1]
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207306